Loading...

DMS Imaging SA

DMSIM.BREURONEXT
Healthcare
Biotechnology
0.02
0.001(6.90%)

DMS Imaging SA (DMSIM.BR) Company Profile & Overview

Explore DMS Imaging SA’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

DMS Imaging SA (DMSIM.BR) Company Profile & Overview

DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.

SectorHealthcare
IndustryBiotechnology
CEOFrank Hazevoets

Contact Information

7 Rue des Chasseurs Ardennais, Liège, 4031

Company Facts

118 Employees
IPO DateMay 11, 2016
CountryBE

Frequently Asked Questions

;